---
title: "如瑞迪博士實驗室在加拿大推出了仿製的 Semaglutide 注射劑"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286635919.md"
description: "藥明康德已在加拿大推出其用於 2 型糖尿病的仿製 Semaglutide 注射劑，成為在獲得加拿大衞生部合規通知後首批推出該產品的公司之一。該注射劑提供 2 毫克和 4 毫克的預填充筆，設計為每週使用一次。首席執行官 Erez Israeli 強調了公司致力於提供高質量 GLP-1 療法並擴大全球市場準入的承諾"
datetime: "2026-05-15T22:23:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286635919.md)
  - [en](https://longbridge.com/en/news/286635919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286635919.md)
---

# 如瑞迪博士實驗室在加拿大推出了仿製的 Semaglutide 注射劑

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada.

The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement.

Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added.

"The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said.

He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said.

"As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets," he noted.

In Canada, Dr Reddy's Semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise, the company said.

It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml.

The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection, the statement said.

### 相關股票

- [RDY.US](https://longbridge.com/zh-HK/quote/RDY.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：如瑞迪博士 ADR(RDY-US) EPS 預估下修至 0.55 元，預估目標價為 13.27 元](https://longbridge.com/zh-HK/news/286277853.md)
- [鉅亨速報 - Factset 最新調查：如瑞迪博士 ADR(RDY-US) EPS 預估下修至 0.64 元，預估目標價為 13.44 元](https://longbridge.com/zh-HK/news/286098145.md)
- [港大團隊開創新型混合療法 提高急性骨髓性白血病患者存活率](https://longbridge.com/zh-HK/news/287004908.md)
- [如瑞迪博士在加拿大推出仿製藥 Semaglutide，擴大 GLP-1 藥物的推廣](https://longbridge.com/zh-HK/news/286652907.md)
- [禮來 orforglipron 可幫助停止 GLP-1 注射劑的人羣維持體重減輕效果](https://longbridge.com/zh-HK/news/286423020.md)